MUC1 and mismatch repair cancer syndrome 1: PEM, a highly selective IgG4-kappa humanized monoclonal antibody against the PD-1 receptor, has shown a high response rate in mCRPC with mismatch repair deficiency, regardless of the primary tumor site [29], and was first approved by the FDA on September 4, 2014.